Please note that during February 2018 the company advised NICE that the Committee for Medicinal Products for Human Use (CHMP) had adopted a negative opinion for neratinib in this indication. Therefore, NICE decided to suspend this appraisal on its work programme. The company advised that they would be appealing the decision and had submitted a re-examination application to the European Medicines Agency. CHMP granted a positive opinion during June 2018 and therefore, this appraisal has been rescheduled into the work programme. The appraisal is anticipated to begin in mid-November 2018 with an evidence submission deadline to NICE of early February 2019.